title: Response to comment by P. Vassilakopoulos and colleagues.
authors.affiliation: Medical University of Vienna, Innsbruck, Austria ulrich.jaeger@meduniwien.ac.at.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Jaeger
authors.affiliation: Assign Data Management and Biostatistics GmbH Assign Group, Innsbruck, Austria.
authors.forename: Michael
authors.initials: M
authors.lastname: Praxmarer
authors.affiliation: Private Medical University Hospital Salzburg, Austria.
authors.forename: Richard
authors.initials: R
authors.lastname: Greil
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008297:Male; D000069283:Rituximab / Q000627:therapeutic use*
chemical_list: D000069283:Rituximab
keywords: aggressive B-cell lymphoma; first remission; randomized trial; rituximab maintenance